Versatile Nanodelivery Platform to Maximize siRNA Combination Therapy.
Ontology highlight
ABSTRACT: The unsatisfactory outcomes of typical multiple cytotoxic chemotherapeutic combination therapies used to treat patients have fostered a need for new unconventional combinations of therapeutic agents. Among the candidates, siRNA has been widely discussed and tested. However, the right time right place codelivery of siRNA with other types of active ingredients is challenging because of the possible differences among their physiochemical and pharmacodynamics properties. To accomplish a synergistic cytotoxic effect, a nanoassembly is thus designed to codeliver siRNA with other therapeutic agents. A siRNA, targeting prosurvival gene for the p75 neurotrophin receptor, and an organelle-fusing peptide, targeting mitochondria, are layered onto a nanotemplate by charge-charge interaction, followed b
SUBMITTER: Lee SK
PROVIDER: S-EPMC5310967 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA